Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
Alessandra Lugaresi,1 Maria di Ioia,1 Daniela Travaglini,1 Erika Pietrolongo,1 Eugenio Pucci,2 Marco Onofrj11Department of Neuroscience and Imaging, University “G d’Annunzio”, Chieti, 2Operative Unit Neurologia ASUR Marche Area Vasta 3, Macerata, ItalyAbstract: Multiple...
Guardado en:
Autores principales: | Lugaresi A, di Ioia M, Travaglini D, Pietrolongo E, Pucci E, Onofrj M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7b438cb53dd941848ca4021e62484fa1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: Fabricio González-Andrade, et al.
Publicado: (2010) -
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
por: Julie A Murphy, et al.
Publicado: (2010) -
The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis
por: Aliza Bitton Ben-Zacharia, et al.
Publicado: (2021) -
A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis
por: Kerstin Hellwig, et al.
Publicado: (2021) -
Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?
por: Mezei Z, et al.
Publicado: (2012)